|
|
Volumn 23, Issue 4, 2005, Pages 400-
|
|
Syrrx acquisition signals maturation of structure-based discovery
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DIPEPTIDYL PEPTIDASE IV;
IMATINIB;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;
PLX 204;
TROXACITABINE;
LIGAND;
PROTEIN;
CHRONIC MYELOID LEUKEMIA;
COMMERCIAL PHENOMENA;
CRYSTALLIZATION;
CRYSTALLOGRAPHY;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SCREENING;
DRUG STRUCTURE;
DRUG TARGETING;
HIGH THROUGHPUT SCREENING;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NOTE;
PRIORITY JOURNAL;
ARTICLE;
BIOTECHNOLOGY;
CHEMICAL STRUCTURE;
CHEMISTRY;
DRUG DESIGN;
ISOLATION AND PURIFICATION;
PROTEIN SYNTHESIS;
STRUCTURE ACTIVITY RELATION;
X RAY CRYSTALLOGRAPHY;
BIOTECHNOLOGY;
CRYSTALLIZATION;
CRYSTALLOGRAPHY, X-RAY;
DRUG DESIGN;
DRUG INDUSTRY;
LIGANDS;
MOLECULAR STRUCTURE;
PROTEIN BIOSYNTHESIS;
PROTEINS;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
|
EID: 23644432399
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0405-400 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|